Dynavax Technologies Corporation raised revenue guidance for the full year 2023. For the year, the company expected HEPLISAV-B net product revenue to be in the range of $200 million to $215 million compared to the prior range of $165 million to $185 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.21 USD | +0.36% | -5.00% | -19.81% |
Apr. 01 | Dynavax Technologies Corporation Announces Chief Financial Officer Changes | CI |
Feb. 23 | Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.81% | 1.47B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- DVAX Stock
- News Dynavax Technologies Corporation
- Dynavax Technologies Corporation Raises Revenue Guidance for the Full Year 2023